{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:54:18Z","timestamp":1792068858430,"version":"4.4.0"},"reference-count":25,"publisher":"Royal College of Psychiatrists","issue":"6","license":[{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec id=\"S0007125023001666_sec_a1\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Phase three trials of the monoclonal antibodies lecanemab and donanemab, which target brain amyloid, have reported statistically significant differences in clinical end-points in early Alzheimer's disease. These drugs are already in use in some countries and are going through the regulatory approval process for use in the UK. Concerns have been raised about the ability of healthcare systems, including those in the UK, to deliver these treatments, considering the resources required for their administration and monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0007125023001666_sec_a2\">\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To estimate the scale of real-world demand for monoclonal antibodies for Alzheimer's disease in the UK.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0007125023001666_sec_a3\" sec-type=\"methods\">\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>We used anonymised patient record databases from two National Health Service trusts for the year 2019 to collect clinical, demographic, cognitive and neuroimaging data for these cohorts. Eligibility for treatment was assessed using the inclusion criteria from the clinical trials of donanemab and lecanemab, with consideration given to diagnosis, cognitive performance, cerebrovascular disease and willingness to receive treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0007125023001666_sec_a4\" sec-type=\"results\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We examined the records of 82 386 people referred to services covering around 2.2 million people. After applying the trial criteria, we estimate that a maximum of 906 people per year would start treatment with monoclonal antibodies in the two services, equating to 30 200 people if extrapolated nationally.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0007125023001666_sec_a5\" sec-type=\"conclusions\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Monoclonal antibody treatments for Alzheimer's disease are likely to present a significant challenge for healthcare services to deliver in terms of the neuroimaging and treatment delivery. The data provided here allows health services to understand the potential demand and plan accordingly.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1192\/bjp.2023.166","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T04:30:20Z","timestamp":1705552220000},"page":"198-204","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":27,"title":["Estimating demand for potential disease-modifying therapies for Alzheimer's disease in the UK"],"prefix":"10.1192","volume":"224","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3231-6663","authenticated-orcid":false,"given":"Axel A. S.","family":"Laurell","sequence":"first","affiliation":[{"name":"University of Cambridge Cambridgeshire and Peterborough NHS Foundation Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin V.","family":"Venkataraman","sequence":"additional","affiliation":[{"name":"King's College London King's College London South London and Maudsley NHS Foundation Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Schmidt","sequence":"additional","affiliation":[{"name":"University of Cambridge"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Montagnese","sequence":"additional","affiliation":[{"name":"University of Cambridge"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9816-1686","authenticated-orcid":false,"given":"Christoph","family":"Mueller","sequence":"additional","affiliation":[{"name":"King's College London South London and Maudsley NHS Foundation Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4435-6397","authenticated-orcid":false,"given":"Robert","family":"Stewart","sequence":"additional","affiliation":[{"name":"King's College London South London and Maudsley NHS Foundation Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Lewis","sequence":"additional","affiliation":[{"name":"Cambridgeshire and Peterborough NHS Foundation Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Mundell","sequence":"additional","affiliation":[{"name":"Cambridgeshire and Peterborough NHS Foundation Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2745-9597","authenticated-orcid":false,"given":"Jeremy D.","family":"Isaacs","sequence":"additional","affiliation":[{"name":"St George's University Hospitals NHS Foundation Trust University of London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mani S.","family":"Krishnan","sequence":"additional","affiliation":[{"name":"Tees, Esk and Wear Valleys NHS Foundation Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8881-4022","authenticated-orcid":false,"given":"Robert","family":"Barber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Rittman","sequence":"additional","affiliation":[{"name":"University of Cambridge"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3427-9487","authenticated-orcid":false,"given":"Benjamin R.","family":"Underwood","sequence":"additional","affiliation":[{"name":"University of Cambridge Cambridgeshire and Peterborough NHS Foundation Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"key":"S0007125023001666_ref5","volume-title":"FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval","year":"2023"},{"key":"S0007125023001666_ref21","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1017\/S104161021700268X","article-title":"Conversion between Addenbrooke's Cognitive Examination III and Mini-Mental State Examination","volume":"30","author":"Mat\u00edas-Guiu","year":"2018","journal-title":"Int Psychogeriatr"},{"key":"S0007125023001666_ref12","first-page":"362","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"S0007125023001666_ref6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.o3010"},{"key":"S0007125023001666_ref14","volume-title":"NHS \u2018Nowhere Near Ready\u2019 to Deliver New Alzheimer's Drug, Doctors Say. The Guardian","author":"Sample","year":"2022"},{"key":"S0007125023001666_ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"S0007125023001666_ref13","first-page":"398","article-title":"Aducanumab: appropriate use recommendations","volume":"8","author":"Cummings","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"key":"S0007125023001666_ref18","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ana.23931","article-title":"Mild cognitive impairment due to Alzheimer disease in the community","volume":"74","author":"Petersen","year":"2013","journal-title":"Ann Neurol"},{"key":"S0007125023001666_ref24","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jalz.2019.04.001","article-title":"Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype","volume":"15","author":"Vermunt","year":"2019","journal-title":"Alzheimers Dement"},{"key":"S0007125023001666_ref7","volume-title":"Cereb Circ Cogn Behav","author":"Isaacs","year":"2022"},{"key":"S0007125023001666_ref3","first-page":"197","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer's disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"S0007125023001666_ref2","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"S0007125023001666_ref19","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/gps.1610","article-title":"The Addenbrooke's Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening","volume":"21","author":"Mioshi","year":"2006","journal-title":"Int J Geriatr Psychiatry"},{"key":"S0007125023001666_ref8","volume-title":"Are We Ready to Deliver Disease Modifying Treatments?","year":"2021"},{"key":"S0007125023001666_ref10","volume-title":"National Audit of Dementia: Memory Assessment Services Spotlight Audit 2021","year":"2022"},{"key":"S0007125023001666_ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100708"},{"key":"S0007125023001666_ref16","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2214\/ajr.149.2.351","article-title":"MR signal abnormalities at 1.5T in Alzheimer's dementia and normal aging","volume":"149","author":"Fazekas","year":"1987","journal-title":"Am J Roentgenol"},{"key":"S0007125023001666_ref22","doi-asserted-by":"publisher","DOI":"10.1192\/pb.bp.113.044263"},{"key":"S0007125023001666_ref23","volume-title":"The 2019 National Memory Service Audit","author":"Cook","year":"2020"},{"key":"S0007125023001666_ref15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207770"},{"key":"S0007125023001666_ref25","volume-title":"Dementia: Assessment, Management, and Support for People Living with Dementia and Their Carers","year":"2018"},{"key":"S0007125023001666_ref20","doi-asserted-by":"publisher","DOI":"10.1159\/000351671"},{"key":"S0007125023001666_ref17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-008721"},{"key":"S0007125023001666_ref9","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.bcp.2013.12.024","article-title":"Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers","volume":"88","author":"Reitz","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"S0007125023001666_ref11","volume-title":"Lecanemab-irmb (LEQEMBI) Criteria for Use February 2023","year":"2023"}],"container-title":["The British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125023001666","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T07:37:17Z","timestamp":1761032237000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125023001666\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0007125023001666"],"URL":"https:\/\/doi.org\/10.1192\/bjp.2023.166","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.11.17.23298682","asserted-by":"object"}]},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,18]]},"assertion":[{"value":"Copyright \u00a9 The Author(s), 2024. Published by Cambridge University Press on behalf of Royal College of Psychiatrists","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http:\/\/creativecommons.org\/licenses\/by\/4.0\/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}